Nephros Ownership

Some institutional investors establish a significant position in stocks such as Nephros in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Nephros, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Check out Stocks Correlation.
  
The market capitalization of Nephros is $17.5 Million. 30% of Nephros outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulation than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or about to change. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Nephros Stock Ownership Analysis

About 47.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.42. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Nephros recorded a loss per share of 0.39. The entity last dividend was issued on the 30th of September 2010. The firm had 1:20 split on the 10th of July 2019. Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey. Nephros operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 34 people. To find out more about Nephros contact Daron Evans at 201 343 5202 or learn more at https://www.nephros.com.

Nephros SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Nephros prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Nephros investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Nephros specific information freely available to individual and institutional investors to make a timely investment decision.
10th of February 2022
Unclassified Corporate Event
View
13th of January 2022
Financial Statements and Exhibits. Regulation FD Disclosure. Results of Operations and Financial Condition
View

Nephros Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nephros insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nephros' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Nephros insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Nephros in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Nephros' short interest history, or implied volatility extrapolated from Nephros options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Nephros using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Check out Stocks Correlation. Note that the Nephros information on this page should be used as a complementary analysis to other Nephros' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Other Tools for Nephros Stock

When running Nephros price analysis, check to measure Nephros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nephros is operating at the current time. Most of Nephros' value examination focuses on studying past and present price action to predict the probability of Nephros' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Nephros' price. Additionally, you may evaluate how the addition of Nephros to your portfolios can decrease your overall portfolio volatility.
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go